Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Overview
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Companies Involved in Therapeutics Development
Clinuvel Pharmaceuticals Ltd
Eton Pharmaceuticals Inc
Mallinckrodt Plc
Mitsubishi Tabe Pharma Corp
Palatin Technologies Inc
Syct Pharma AB
Viewpoint Molecular Targeting LLC
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Drug Profiles
afamelanotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-1189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUV-9900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dersimelagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Parvysmelanotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-8177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-8331 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-9643 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VMT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Dormant Products
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Discontinued Products
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Product Development Milestones
Featured News & Press Releases
Jul 07, 2021: Syct Pharma announces additiol data from the phase 2a trial of AP1189 in covid-19 infected patients and reminds of magement call to discuss results
Jul 02, 2021: Syct Pharma hosts conference call on positive data from a phase 2a trial of AP1189 in Covid-19 infected patients
Jul 01, 2021: Mallinckrodt announces inclusion of Acthar Gel (Repository Corticotropin Injection) in New European Respiratory Society (ERS) treatment guidelines for patients with pulmory sarcoidosis
Jun 30, 2021: Syct Pharma announces positive data from a phase 2a trial of AP1189 in covid-19 infected patients
Jun 29, 2021: Palatin announces positive end-of-phase 2 meeting with FDA on PL9643 for the treatment of dry eye disease
Jun 23, 2021: Syct Pharma files patent applications related to AP1189 derived APIs and oral formulations
Jun 07, 2021: First stroke patient treated with afamelanotide
Jun 01, 2021: Syct Pharma completes recruitment and dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients
May 14, 2021: Palatin hosting key opinion leader webir in role of melanocortin agonists in inflammation and the treatment of ocular indications
May 14, 2021: Syct Pharma initiates collaboration on pharmacogenetic aspects of AP1189 compound in Rheumatoid arthritis with Barts and London School of Medicine, Queen Mary University of London.
May 04, 2021: Syct Pharma expands AP1189 BEGIN study in rheumatoid arthritis UK version
May 03, 2021: Mallinckrodt presents data evaluating Acthar Gel (Repository Corticotropin Injection) for the treatment of severe keratitis at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting
Apr 20, 2021: Palatin announces two presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Apr 13, 2021: Syct strengthens IP portfolio - Receives “Intention to Grant” from the European Patent Office for a key patent covering AP1189 English version
Mar 31, 2021: Phase-2 clinical trial of MT-7117 initiated in the U.S., Cada, and Europe for the rare disease, diffuse cutaneous systemic sclerosis (dcSSc)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Clinuvel Pharmaceuticals Ltd, 2021
Pipeline by Eton Pharmaceuticals Inc, 2021
Pipeline by Mallinckrodt Plc, 2021
Pipeline by Mitsubishi Tanabe Pharma Corp, 2021
Pipeline by Palatin Technologies Inc, 2021
Pipeline by SynAct Pharma AB, 2021
Pipeline by Viewpoint Molecular Targeting LLC, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021